Mental state: psychotic symptoms Average total score (PANSS, higher score = worse, scale from 30‐210) Long‐term (up to 7 years) · people in the prodromal stage of psychosis
1 finding from 1 review
Behaviour: clinically important change in behaviour · people in the prodromal stage of psychosis
1 finding from 1 review
Adverse effects: neurological, extrapyramidal UKU (events) Medium‐term · people in the prodromal stage of psychosis
Group A: omega‐3 fatty acids showed no clear difference in adverse effects: neurological, extrapyramidal UKU (events) Medium‐term compared with placebo (low certainty).
1 finding from 1 review
Quality of life: clinically important change in quality of life · people in the prodromal stage of psychosis
1 finding from 1 review
Satisfaction with treatment: 1. Leaving the study early ‐ long term · people in the prodromal stage of psychosis
Group A: omega‐3 fatty acids showed no clear difference in satisfaction with treatment: leaving the study early Long‐term… compared with placebo (low certainty).
1 finding from 1 review
Global state: clinically important change in global state · people in the prodromal stage of psychosis
1 finding from 1 review
Prodromal symptoms: transition to psychosis Endpoint data (events) · people in the prodromal stage of psychosis
It is very uncertain whether group B antipsychotic drugs: olanzapine + supportive intervention changes prodromal symptoms: transition to psychosis Endpoint data, (events)… compared with placebo + supportive intervention (very low certainty).
1 finding from 1 review
Global effect: 1a. Medium‐term ‐ Average end point score on various outcomes ‐ CGI‐severity (low = favourable) ( · people in the prodromal stage of psychosis
1 finding from 1 review
Mental state: psychosis risk symptoms SOPS total (higher score = worse, scale from: 0‐114) · people in the prodromal stage of psychosis
1 finding from 1 review
Behaviour: clinically important change in behaviour · people in the prodromal stage of psychosis
1 finding from 1 review
Weight gain · people in the prodromal stage of psychosis
1 finding from 1 review
Quality of life: clinically important change in quality of life · people in the prodromal stage of psychosis
1 finding from 1 review
Satisfaction and acceptability of treatment (medium term) ‐ leaving the study early · people in the prodromal stage of psychosis
It is very uncertain whether group B antipsychotic drugs: olanzapine + supportive intervention changes satisfaction with treatment: leaving the study early Endpoint data… compared with placebo + supportive intervention (very low certainty).
1 finding from 1 review
Mental state: psychosis risk symptoms SOPS total (higher score = worse, scale from: 0‐114) · people in the prodromal stage of psychosis
1 finding from 1 review
no estimate extracted
1 study · 8 participants
Very low
Prodromal symptoms: transition to psychosis Endpoint data (events) · people in the prodromal stage of psychosis
It is very uncertain whether group B cognitive behavioural therapy: cognitive behavioural therapy… changes prodromal symptoms: transition to psychosis Endpoint data (events) compared with cognitive behavioural therapy + placebo (very low certainty).
1 finding from 1 review
Global state: clinically important change in global state · people in the prodromal stage of psychosis
1 finding from 1 review
Global state: Response ‐ proxy outcome ‐ mental state: 1. General ‐ average score (Brief Psychiatric Rating Scale by over 24 weeks · people in the prodromal stage of psychosis
1 finding from 1 review
Behaviour: clinically important change in behaviour · people in the prodromal stage of psychosis
1 finding from 1 review
Behaviour: clinically important change in behaviour · people in the prodromal stage of psychosis
1 finding from 1 review
Adverse effects: specific ‐ doctors' assessment of adverse effects UKU (events) Medium‐term · people in the prodromal stage of psychosis
It is very uncertain whether group B cognitive behavioural therapy: cognitive behavioural therapy… changes adverse effects: specific ‐ doctors' assessment of adverse effects… compared with cognitive behavioural therapy + placebo (very low certainty).
1 finding from 1 review